Juan José Marín-Peñalver

Endocrinology, Diabetes and Metabolism · 2016

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Juan José Marín-Peñalver trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. C. Bailey
  2. John B. Buse
  3. D. Nathan
  4. Z. Bloomgarden
  5. J. List

Papers from Juan José Marín-Peñalver's perspective

Ordered by how strongly the researchers Juan José Marín-Peñalver trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
  2. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (British medical journal)
  3. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. (Cochrane Database of Systematic Reviews)
  4. 10-year follow-up of intensive glucose control in type 2 diabetes. (New England Journal of Medicine)
  5. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (New England Journal of Medicine)
  6. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (New England Journal of Medicine)
  7. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. (New England Journal of Medicine)
  8. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3… (The Lancet)
  9. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise (Diabetes, obesity and metabolism)
  10. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (Diabetes Care)

Their papers